CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Azora Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Azora Therapeutics, Inc.
4870 Sadler Road, Suite 300
Phone: (804) 487-8196p:804 487-8196 GLEN ALLEN, VA  23060  United States Ticker: AZRAZR
Business Summary
Azora Therapeutics, Inc., formerly Adial Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The Company is developing differentiated therapies for serious immune-mediated and inflammatory diseases. Its pipeline is AT177. AT177 is an investigational oral drug being developed for inflammatory bowel diseases, with an initial focus on ulcerative colitis. AT177 can deliver potent, colon-targeted Aryl-hydrocarbon Receptor (AhR) agonism directly to the site of disease. It is designed to capture the therapeutic benefits of AhR activation while minimizing systemic exposure. AT177's lead indication is in ulcerative colitis (UC), which is a chronic inflammatory disease of the colon and rectum. It is advancing AT177, a fully synthetic, patented, oral colon-targeted AhR agonist. The Aryl Hydrocarbon receptor (AhR) governs mucosal immunity and epithelial barrier integrity in the gut.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer MatthewDavidson 42 11/3/2026 6/11/2026
Chief Financial Officer CeliaEconomides 47 10/28/2026 10/28/2026
Chief Scientific Officer DavidRubenstein 10/28/2026 10/28/2026
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Azora Therapeutics, Inc. 4267 Valley Meadow Rd Encino CA United States

Business Names
Business Name
ADIL
Azora Therapeutics, Inc.
AZR

General Information
Number of Employees: 5 (As of 12/31/2025)
Outstanding Shares: 14,243,129 (As of 11/4/2026)
Shareholders: 85
Stock Exchange: NASD
Federal Tax Id: 823074668
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026